

Special Issue

The Protection and Toxic Reactions of Dietary Supplements: Focusing on Molecular Mechanisms and Treatment

Message from the Guest Editor

Although most people believe that dietary supplements can help us become more healthy, serious toxicities do occur due to the consumption of too many supplements. Some supplements can also cause problems if taken with certain medicines. For example, vitamins C and E may reduce the effectiveness of some chemotherapy drugs. Complementary medicine is frequently integrated with conventional medicine. Prescription medicines are thoroughly tested before receiving regulatory approval, but despite this, real-world experience reveals undetectable adverse events in clinical trials. Complementary and alternative medicine are considered non-toxic by consumers. However, many of them might produce adverse reactions or interact with prescription medicine. This Special Issue aims to report all the adverse effects of dietary supplements. We welcome the discussion of adverse events for commonly used supplements such as vitamins, minerals, plant extracts, and so on. We will also look into the protective or harmful effects of complementary and alternative use.

Guest Editor

Prof. Dr. Neuman Manuela

In Vitro Drug Safety and Biotechnology, Département of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON M2R 1W6, Canada

Deadline for manuscript submissions

closed (28 February 2025)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/194226

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.